Qudexy Xr

Migraine, Caloric Restriction, High cholesterol + 16 more

Treatment

20 Active Studies for Qudexy Xr

What is Qudexy Xr

Topiramate

The Generic name of this drug

Treatment Summary

Topiramate is a medication used to control epilepsy and prevent migraine headaches. It was first approved by the FDA in 1996 and later approved for migraine prevention in adults in 2004. It is also used in combination with another drug, phentermine, to help adults lose weight. It has an unusual chemical structure composed of sulfamate and oxygen, which was discovered by chance during the development of an antidiabetic medication.

Topamax

is the brand name

image of different drug pills on a surface

Qudexy Xr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Topamax

Topiramate

1997

526

Effectiveness

How Qudexy Xr Affects Patients

Topiramate helps to prevent seizures and migraine symptoms by decreasing the activity of neurons in the brain. However, it can also cause metabolic acidosis, changes in mood, suicidal thoughts or attempts, and kidney stones. Taking topiramate with another drug called valproic acid can also lead to hypothermia.

How Qudexy Xr works in the body

Seizures are caused by an electrical disruption in the brain, which causes a temporary disruption of normal brain activity. Topiramate is used to treat these seizures and migraines, although the exact way it works is not fully understood. It likely works by blocking sodium channels in the brain and increasing activity of inhibitory GABA-A receptors while reducing activity of stimulating glutamate receptors. This decreases the electrical signals in the brain, preventing seizures and migraines. Topiramate also blocks some carbonic anhydrase isozymes, but it is unclear what impact this has.

When to interrupt dosage

The recommended dosage of Qudexy Xr is contingent upon the diagnosed condition, including Seizures, Weight Reduction and Tonic - clonic seizures. The quantity of dosage fluctuates as per the procedure of delivery (e.g. Tablet, coated or Tablet) specified in the table underneath.

Condition

Dosage

Administration

Alcoholism

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Obesity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Exercise

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Lennox Gastaut Syndrome

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Migraine

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Caloric Restriction

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

High cholesterol

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Obesity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

at least one weight-related comorbid condition

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Migraine Disorders

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Obesity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Seizures

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Type 2 Diabetes

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Hypertensive disease

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Epilepsy

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Weight Loss

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

increase in physical activity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Mood Disorders

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Chronic Weight Management therapy

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated, Solution - Oral, Solution, Tablet, coated - Oral

Warnings

Qudexy Xr Contraindications

Condition

Risk Level

Notes

Acidosis

Do Not Combine

There are 20 known major drug interactions with Qudexy Xr.

Common Qudexy Xr Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Topiramate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Topiramate.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be increased when combined with Topiramate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Topiramate.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Topiramate.

Qudexy Xr Toxicity & Overdose Risk

The toxic dose of topiramate in rats is above 1500 mg/kg. People who overdose on topiramate may experience symptoms such as low blood pressure, extreme acidity in the body, coma, stomach pain, vision problems, seizures, drowsiness, trouble speaking, confusion, dizziness, agitation, and depression. If the overdose is recent, doctors may suggest vomiting or pumping the stomach, as well as providing supportive care with activated charcoal and hemodialysis.

Qudexy Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Qudexy Xr?

313 active clinical trials are currently being conducted to assess the potential of Qudexy Xr to ameliorate Type 2 Diabetes, Migraine and Exercise-related issues.

Condition

Clinical Trials

Trial Phases

Exercise

53 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Weight Loss

0 Actively Recruiting

Mood Disorders

0 Actively Recruiting

Migraine

48 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Obesity

0 Actively Recruiting

Chronic Weight Management therapy

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Hypertensive disease

30 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Seizures

4 Actively Recruiting

Phase 3, Phase 2, Phase 1

High cholesterol

0 Actively Recruiting

Obesity

0 Actively Recruiting

at least one weight-related comorbid condition

0 Actively Recruiting

Lennox Gastaut Syndrome

2 Actively Recruiting

Phase 1, Phase 2, Phase 4

Obesity

0 Actively Recruiting

Caloric Restriction

0 Actively Recruiting

Epilepsy

0 Actively Recruiting

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Type 2 Diabetes

151 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

increase in physical activity

0 Actively Recruiting

Qudexy Xr Reviews: What are patients saying about Qudexy Xr?

5

Patient Review

9/11/2017

Qudexy Xr for Migraine Prevention

I use this because I have basilar migraines and i was on 100 mg of topomax xr but it stopped working for me so my neurologist bumped me up to 150mg to quedexy and it works great for me i have had no probelms! when i was taking the topomax I had tingling in my fingers and toes and knees and I also had nightmares for a month everytime I closed my eyes, but with quedexy I have never felt better!

2.7

Patient Review

10/17/2016

Qudexy Xr for Migraine Prevention

I was previously taking topamax 100mg, but my doctor switched me to Qudexy at my annual visit. I found that I wasn't in a fog anymore, which was great! However, I experienced terrible stomach issues and bad tingling in my arms and legs. I tried staying with the medication for 3 weeks, but the stomach problems were too much to handle. I'm currently trying Trokendi to see if it will be more effective.

2

Patient Review

1/14/2021

Qudexy Xr for Migraine Prevention

Although this medication did help to lessen my migraines by half, the hair loss after just three months was not worth it. Additionally, I frequently felt tingling in my fingers and toes while taking this drug.

1.7

Patient Review

7/15/2016

Qudexy Xr for Migraine Prevention

I experienced a lot of negative side effects, like nausea and suicidal thoughts. This medication was ineffective for me, so I do not recommend it to others who are looking for relief from migraines.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about qudexy xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Qudexy XR?

"The following effects may occur: fatigue, drowsiness, dizziness, loss of coordination, tingling in the extremities, loss of appetite, changes in food taste, diarrhea, and weight loss."

Answered by AI

What is Qudexy XR used for?

"Qudexy XR is a prescription medicine that can be used to prevent migraine headaches in adults and adolescents 12 years and older, and to treat certain types of seizures (partial-onset seizures and primary generalized tonic-clonic seizures) in adults and children 2 years and older."

Answered by AI

Is Qudexy the same as topiramate?

"The active ingredient in both Topiramate Extended-Release Capsules and Qudexy® XR is topiramate. Topiramate Extended-Release Capsules are manufactured by Upsher-Smith, while Qudexy® XR is manufactured by UCB, Inc."

Answered by AI

Is Qudexy XR used for weight loss?

"No, you should not use Qudexy XR for weight loss. Although weight loss is a potential side effect of the medication, the main purpose of Qudexy XR is to help people with epilepsy or those who suffer from migraines."

Answered by AI

Clinical Trials for Qudexy Xr

Image of University of Texas Medical Branch in Galveston, United States.

Middle Meningeal Artery Stimulation for Migraine

18 - 100
All Sexes
Galveston, TX

This study is testing a new way to help with migraine headaches. Researchers want to see if it's safe and doable to stimulate a blood vessel in the head (called the middle meningeal artery) with microcatheters and microwires. This has never been done before for migraines and is an investigational treatment that is not part of standard migraine treatment. This stimulation would happen just before giving the standard lidocaine treatment, which is already routinely used for migraines. The goal is to see whether this new step could help improve headache outcomes. Two FDA-cleared medical devices will be used, the Cadwell Cascade 32 PRO and the Cadwell Guardian IONM System, to perform the stimulation and monitoring. In this study, the Cascade 32 PRO will be used in a way that is not part of its usual approved purpose (this is called "off-label" use) to gently deliver electrical pulses through a microcatheter. The Cadwell Guardian IONM System will be used in its normal, FDAapproved way for continuous monitoring during stimulation.

Recruiting
Has No Placebo

University of Texas Medical Branch

Peter Kan, MD,MPH

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Have you considered Qudexy Xr clinical trials?

We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.
Go to Trials
Image of American University in Washington D.C., United States.

Dietary Intervention for Migraine

18 - 75
All Sexes
Washington D.C., United States

The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary glutamate intake may influence processes involved in migraine, such as brain excitation, inflammation, and oxidative stress. The main questions this study aims to answer are: Does following a low-glutamate diet reduce the number of migraine days and the severity and duration of migraine attacks, and improve quality of life? Are improvements in migraine symptoms associated with changes in blood-based biological markers related to migraine activity? Researchers will compare participants assigned to the low-glutamate diet with participants assigned to a wait-list control group to evaluate differences in migraine outcomes and related biological measures. Participants will: Complete a baseline run-in period while tracking headaches using a daily migraine diary Either follow a low-glutamate dietary intervention or continue their usual diet as part of a wait-list control Complete standardized questionnaires related to migraine symptoms and quality of life Provide blood samples for laboratory analyses Undergo neuroimaging assessments (for a subset of participants)

Waitlist Available
Has No Placebo

American University

Image of Faculty of Health Sciences in Winnipeg, Canada.

Saskatoon Berries for Type 2 Diabetes

18 - 74
All Sexes
Winnipeg, Canada

Diabetes becomes epidemic in worldwide countries. Diabetes Canada indicated that 30% of adults in Manitoba are diabetes or prediabetes. Nine out of ten diabetic patients are type 2 diabetes (T2D). T2D is characterized by insulin resistance and obesity. Uncontrolled diabetes leads to serious consequences including heart attack, stroke, chronic renal failure, liver failure, blindness and low limb amputation. Most of hypoglycemic medications have certain side effects. Natural foods or nutraceuticals with hypoglycemic potential are expected to provide a safer management for diabetic patients. Saskatoon berry is a popular fruit in Canadian Prairie and Northern states in USA. Previous studies in the investigator's group demonstrated Saskatoon berry (SB) powder attenuated hyperglycemia, hyperlipidemia, insulin resistance, inflammation, liver steatosis and gut dysbiosis in diet-induced insulin resistant mice, a model for T2D. The findings of the glucose and lipid lowering or liver protective effects of SB powder have been supported by another group in Australia in high fat fed rats. Preliminary studies by the investigators in 20 healthy subjects demonstrated that dried whole SB (40 g/day for 10 weeks) significantly reduced fasting plasma glucose, total and LDL-cholesterol, systolic blood pressure, and increased plasma glucagon-like peptide compared to baseline, which was associated with increased intake of total fiber and decreased intake of saturated fat. The changes in metabolic and vascular variables significantly correlated with the alterations in gut microbiota The combination of findings suggest that SB is good candidate of prebiotic functional food as a supplemental remedy for reducing the risk for metabolic syndrome and preventing or managing T2D. The effect of Saskatoon berry and its products on metabolic disorders have not been studied in diabetic subjects. The investigators propose to examine the effects of oral administration of freeze-dried whole SB on glucose metabolism, insulin resistance and gut microbiota in untreated prediabetes and new type 2 diabetic patients compared to a control dried fruit in a randomized controlled trial.

Waitlist Available
Dietary Supplement

Faculty of Health Sciences

Image of Arkansas Children's Research Institute in Little Rock, United States.

We Move with Windy for Motor Skills

Any Age
All Sexes
Little Rock, AR

The long-term goal of this project is to learn whether a tailored physical activity program is practical, enjoyable, and helpful for families, and whether it has the potential to improve children's physical development and health. Before launching a large study, the research team completed several early phases to make sure the program met families' needs. First, a needs assessment was conducted with mothers to understand barriers to physical activity and what types of support would be most useful. Using this feedback, the program was refined and tested with three mother-child pairs over six weeks. Finally, there was an 18-week pilot randomized trial to examine feasibility and acceptability. Researchers are now conducting a larger randomized trial with up to 266 families. Half of the families are randomly assigned to receive the physical activity program, and half to a comparison group. The program combines fun, age-appropriate movement activities for children with practical support for parents. Sessions focus on building core movement skills such as jumping, balancing, running, and throwing, while also encouraging confidence, coordination, and enjoyment of being active. Activities can be adapted to each child's ability and home environment, making the program realistic for busy families. The program includes both in-person sessions and technology-based activities. In-person sessions provide hands-on support for learning new skills. Technology-based activities offer simple ideas families can use at home or during daily routines, such as hopping games, balance challenges, or quick movement breaks. Because parents in earlier phases wanted nutrition support, in-person sessions also includes a brief, child-friendly exposure to fruits and vegetables, along with simple recipes. A "Tasting Party" at the start of the program allows children to try different foods, and Veggie Meter scans at the beginning and end of the study help track changes in fruit and vegetable intake. Overall, this study will help determine whether a family-tailored physical activity program is a promising approach to improving physical activity, movement skills, and early health indicators in young children born to mothers with obesity.

Recruiting
Has No Placebo

Arkansas Children's Research Institute

Taren Swindle

Image of Arkansas Children's Research Institute in Little Rock, United States.

Exercise Program for Pregnant Women

18+
Female
Little Rock, AR

Regular physical activity during pregnancy is safe and offers many health benefits for both mothers and their babies. Research over the past decade shows that exercise can help pregnant women gain a healthy amount of weight, lower their risk of gestational diabetes and high blood pressure, and reduce stress, anxiety, and symptoms of postpartum depression. Babies also benefit when their mothers are active, with lower risks of preterm birth, unhealthy birth size, and childhood obesity. Despite this strong evidence, very few exercise programs for pregnant women have been tested in real-world community settings, such as fitness centers, community health programs, or local organizations. Even fewer studies explain how these programs were delivered or what helped them succeed. Without this information, it is difficult for communities and health programs to offer exercise support that is both effective and practical for pregnant women. To address this gap, the research team adapted an evidence-based program called EXPECTING so it could be delivered by community organizations. Previous participants and community advisors helped to understand what changes were needed to make the program easier to offer while still keeping it safe and effective. The core parts of the program, including the type, amount, and intensity of aerobic and strength-building exercises, remained the same and are based on established pregnancy exercise guidelines. The adapted program, called COMMUNITY EXPECTING, includes both aerobic exercise and resistance training. The research team also developed specific supports to help community instructors deliver the program consistently and with confidence. All program components have already been tested in community settings and shown to be realistic, acceptable, and delivered as planned. This study will examine whether offering a structured exercise program in community settings helps pregnant women be more physically active than usual prenatal care alone. We will also assess whether the program can be delivered successfully and in a way that works for both participants and community providers. The results will help determine whether COMMUNITY EXPECTING is a practical approach for supporting healthy pregnancies in real-world settings.

Recruiting
Has No Placebo

Arkansas Children's Research Institute

Taren Swindle

Have you considered Qudexy Xr clinical trials?

We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.
Go to Trials
Image of Central Research Associates - Flourish - PPDS in Birmingham, United States.

CX11 for Type 2 Diabetes

18 - 75
All Sexes
Birmingham, AL

This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.

Phase 2
Waitlist Available

Central Research Associates - Flourish - PPDS (+29 Sites)

Corxel Pharmaceuticals

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Have you considered Qudexy Xr clinical trials?

We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.
Go to Trials